Drug intelligence / Profile preview

PTH-rhMSC

Development stage: Unknown
Lead developer: Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
Modality: Cell Therapies, Gene Therapies
Administration: Intravenous, Subcutaneous, Transdermal, Parenteral

Overview

PTH-rhMSC is an investigational genetically modified cell therapy consisting of recombinant human mesenchymal stem cells (rhMSCs) engineered to express parathyroid hormone (PTH). Developed by the Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine, the therapy is designed to provide a sustained, physiological release of PTH to regulate calcium and phosphate homeostasis. It is currently being evaluated in a Phase 1/2 clinical trial in China as a potential treatment for hypoparathyroidism, aiming to offer an alternative or supportive approach to standard calcium and calcitriol supplementation.

Other names: PTH recombinant human mesenchymal stem cellsPTH-rhMSCs

Beyond the preview

Go deeper on PTH-rhMSC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTH-rhMSC.

Explore the full profile